Help make the NeuroSens coverage of MSMilan 2023 (The 9th Joint ECTRIMS-ACTRIMS Meeting) relevant to you.
Complete the survey below to tell us what topics are of greatest interest to you. Read More
Latest News
K-index a predictor of T2 lesions in CIS, RIS
September 14, 2023A new study has reported that the kappa free light chain index (K-index) can predict the occurrence of new T2 lesions in subjects with clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) (Levraut et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200156). The K-index was also useful to predict clinical events in CIS. Read More
TERIS trial: final results
September 7, 2023The TERIS trial of teriflunomide in individuals with radiologically isolated syndrome (RIS) has reported that treatment significantly prolonged the time to a first clinical event by 63% versus placebo (Lebrun-Frenay et al. JAMA Neurol, epublished August 21, 2023). Read More
New ECTRIMS/EAN recommendations for vaccination in MS patients
September 5, 2023The European Committee for Treatment and Research in MS (ECTRIMS) and the European Academy of Neurology (EAN) have published their first recommendations on vaccination in people with MS (Otero-Romero et al. Eur J Neurol 2023;30:2144-2176). The following is a summary of key recommendations for patients receiving higher-efficacy disease-modifying therapies (DMTs). Read More